New drug duo shows promise against tough head and neck cancers
NCT ID NCT03468218
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intravenously and by mouth, and researchers track tumor response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
- Can a Three-Pronged attack shrink Hard-to-Treat head and neck cancers?
- Sharper radiation boost aims to tackle head and neck cancers that return
- New combo attack: immunotherapy plus chemo before surgery for head and neck cancer
- New drug cocktail shows promise for tough head and neck cancers
- Can a smaller dose of this cancer drug still work? new trial aims to find out